Pembrolizumab in endometrial cancer: Where we stand now

被引：13

作者：

Aravantinou-Fatorou, Aikaterini ^{[1
]}

Andrikopoulou, Angeliki ^{[2
]}

Liontos, Michael ^{[2
]}

Fiste, Oraianthi ^{[2
]}

Georgakopoulou, Vasiliki E. ^{[1
]}

Dimopoulos, Meletios-Athanasios ^{[2
]}

Gavriatopoulou, Maria ^{[2
]}

Zagouri, Flora ^{[2
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Sch Med, Laiko Gen Hosp, Dept Med 1, Athens 11527, Greece

[2] Natl & Kapodistrian Univ Athens, Sch Med, Alexandra Hosp, Dept Clin Therapeut, 80 Vasilissis Sofias Ave, Athens 11528, Greece

来源：

ONCOLOGY LETTERS | 2021年 / 22卷 / 06期

关键词：

endometrial cancer; anti-PD1; treatment; polymerase epsilon-mutated cancer; microsatellite instability; biomarkers; ANTITUMOR ACTIVITIES; PD-L1; EXPRESSION; THERAPY; IMMUNOTHERAPY; CARCINOMA; CHEMOTHERAPY; INHIBITOR; RADIATION; SAFETY; IPILIMUMAB;

D O I：

10.3892/ol.2021.13082

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recently, immunotherapy has shown promising results in solid tumors. To the best of our knowledge, this is the first systematic review of published literature synthesizing all the available data and evaluating both the efficacy and safety of pembrolizumab in endometrial cancer. The present study was performed in accordance with the PRISMA guidelines. Eligible articles were identified by searching the MEDLINE and ClinicalTrials.gov databases, using a predefined combination of the terms 'endometrial cancer' and 'pembrolizumab'. Overall, nine articles incorporating data from 712 patients were eligible. Pembrolizumab was demonstrated to be an effective and safe therapeutic option for the management of advanced/metastatic endometrial cancer. Results of ongoing trials evaluating either pembrolizumab alone or in combination with other antineoplastic regimens are expected to confirm its efficacy in this setting of patients. Pembrolizumab appears to be both durable and robust in endometrial cancer. However, there is an emerging need for novel predictive biomarkers to guide clinical practice.

引用

页数：12

共 77 条

[11] Complete Clinical Response in Stage IVB Endometrioid Endometrial Carcinoma after First-Line Pembrolizumab Therapy: Report of a Case with Isolated Loss of PMS2 Protein [J].

Carvalho, Jesus Paula ;

Del Giglio, Auro ;

Achatz, Maria Isabel ;

Carvalho, Filomena Marino .

CASE REPORTS IN ONCOLOGY, 2020, 13 (03) :1067-1074

[12] Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer [J].

Chan, John K. ;

Lakomy, David S. ;

McDonald, Yassmina ;

Kapp, Daniel S. .

GYNECOLOGIC ONCOLOGY REPORTS, 2020, 33

[13] Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies [J].

Choi, Min Chul ;

Moon, Yong Wha ;

Jung, Sang Geun ;

Park, Hyun ;

Joo, Won Duk ;

Song, Seung Hun ;

Lee, Chan ;

Kim, Gwangil ;

Kim, Kyoung Ah .

YONSEI MEDICAL JOURNAL, 2020, 61 (10) :844-850

[14]

ClinicalTrials.gov, 2021, PEMBR MK 3475 PLUS L

[15]

ClinicalTrials.gov, 2021, PEMBR MK 3475 PLUS L

[16] ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up [J].

Colombo, N. ;

Creutzberg, C. ;

Amant, F. ;

Bosse, T. ;

Gonzalez-Martin, A. ;

Ledermann, J. ;

Marth, C. ;

Nout, R. ;

Querleu, D. ;

Mirza, M. R. ;

Sessa, C. .

ANNALS OF ONCOLOGY, 2016, 27 (01) :16-41

[17] A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation [J].

Danley, Kelsey ;

Schmitz, Karen ;

Ghai, Ritu ;

Sclamberg, Joy S. ;

Buckingham, Lela E. ;

Burgess, Kelly ;

Kuzel, Timothy M. ;

Usha, Lydia .

ONCOLOGIST, 2021, 26 (10) :811-817

[18] Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline BRCA1 Mutation [J].

Dizon, Don S. ;

Dias-Santagata, Dora ;

Bregar, Amy ;

Sullivan, Laura ;

Filipi, Jennifer ;

DiTavi, Elizabeth ;

Miller, Lucy ;

Ellisen, Leif ;

Birrer, Michael ;

DelCarmen, Marcela .

ONCOLOGIST, 2018, 23 (06) :650-653

[19] Improving oncologic outcomes for women with endometrial cancer: Realigning our sights [J].

Dowdy, Sean C. .

GYNECOLOGIC ONCOLOGY, 2014, 133 (02) :370-374

[20]

Fader A., 2016, Gynecol. Oncol, V141, P206, DOI [DOI 10.1016/J.YGYNO.2016.04.532, 10.1016/j.ygyno.2016.04.532]

← 1 2 3 4 5 6 7 8 →